Sorafenib in Treating Patients With Advanced Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Epistemonikos ID: f52f91a9172ab5541590feaefba1c00dc9da1fc8
First added on: May 04, 2024